Angiogenesis does not only depend on endothelial cell invasion and proliferation: it also requires pericyte coverage of vascular sprouts for vessel stabilization 1, 2 . These processes are coordinated by vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) through their cognate receptors on endothelial cells and vascular smooth muscle cells (VSMCs), respectively 3, 4 . PDGF induces neovascularization by priming VSMCs/pericytes to release proangiogenic mediators [5] [6] [7] . Although VEGF directly stimulates endothelial cell proliferation and migration, its role in pericyte biology is less clear. Here we define a role for VEGF as an inhibitor of neovascularization on the basis of its capacity to disrupt VSMC function. Specifically, under conditions of PDGF-mediated angiogenesis, VEGF ablates pericyte coverage of nascent vascular sprouts, leading to vessel destabilization. At the molecular level, VEGF-mediated activation of VEGF-R2 suppresses PDGF-Rb signalling in VSMCs through the assembly of a previously undescribed receptor complex consisting of PDGF-Rb and VEGF-R2. Inhibition of VEGF-R2 not only prevents assembly of this receptor complex but also restores angiogenesis in tissues exposed to both VEGF and PDGF. Finally, genetic deletion of tumour cell VEGF disrupts PDGF-Rb/VEGF-R2 complex formation and increases tumour vessel maturation. These findings underscore the importance of VSMCs/pericytes in neovascularization 8, 9 and reveal a dichotomous role for VEGF and VEGF-R2 signalling as both a promoter of endothelial cell function and a negative regulator of VSMCs and vessel maturation.
VEGF and PDGF contribute to angiogenesis and vessel stabilization by activating endothelial cells and VSMCs respectively, suggesting that a combination of these factors might elicit a synergistic response. To test this directly in angiogenesis models, PDGF, VEGF or both were mixed with Matrigel and implanted subcutaneously into mice or topically applied to the chorioallantoic membrane (CAM) of 10-day-old chick embryos. As expected, PDGF-BB or VEGF, at an optimal angiogenic dose ( Supplementary Fig. 1a, b ), promotes robust neovascularization (Fig. 1a) . Surprisingly, the 
angiogenesis through VEGF-R2. a, Upper: vessel growth into Matrigel as measured by CD-31 1 area; *P , 0.02; lower: branch points quantified on filter paper impregnated with saline or growth factors placed on embryonic day-10 chick CAMs; *P , 0.02, **P , 0.05, results from one-way analysis of variance (ANOVA). Further images are displayed in Supplementary Fig. 1d . b, Upper: vessel growth into Matrigel as in a, with the application of inhibitors; *P , 0.001, **P , 0.001; lower: branch points quantified on filter paper impregnated with saline or growth factor as in a, with the application of inhibitors; *P , 0.02, results from two-way ANOVA, **P , 0.05; right: confocal microscopy of Matrigel from mice injected intravenously with fluorescent Griffonia lectin; scale bar, 100 mm. c, CD-311 area quantified by image analysis of Matrigel (right panel) impregnated with saline or growth factor implanted into mice infected with adenovirus expressing green fluorescent protein (GFP) only or GFP and truncated VEGF-combination of these cytokines results in complete suppression of angiogenesis ( Fig. 1a ). Inhibition of angiogenesis is not likely due to excessive proliferation of mural or stromal cells, because PDGF and VEGF each combine with bFGF to produce an increased angiogenic response ( Fig. 1a) 10 . Thus, a specific antagonistic relationship exists between PDGF and VEGF during neovascularization.
We next considered whether PDGF or VEGF receptors contribute to the antagonistic effects of combined VEGF/PDGF treatment on neovascularization. After PDGF receptor blockade, we observed suppression of angiogenesis in the presence of either growth factor ( Fig. 1b) , consistent with a role for PDGF in the release of pro-angiogenic factors and the recruitment of VSMCs/pericytes to nascent endothelial cell sprouts 11, 12 . Although combined PDGF/VEGF stimulation leads to the appearance of tenuous and small-calibre vascular sprouts on CAMs at 48 h, a complete absence of new vessel growth is evident on CAMs by 72 h ( Fig. 1b and Supplementary Fig. 1c ). Thus, combined PDGF/ VEGF treatment initiates vessel sprouting but not a durable vascular response.
To assess the role of VEGF-R2 as a negative regulator of pericyte function, Matrigel and CAM tissues were treated with either a VEGF-R2 kinase inhibitor or anti-VEGF-R2 and stimulated with PDGF, VEGF or both. As expected, either inhibitor disrupts VEGF-but not PDGF-mediated angiogenesis in both models ( Fig. 1b) 13 . Interestingly, after PDGF/VEGF treatment, VEGF-R2 inhibition restores angiogenesis to a level achieved with either growth factor alone ( Fig. 1b ), suggesting that under conditions of VEGF/PDGF stimulation, VEGF-R2 negatively regulates neovascularization. To validate these observations, mice were injected with Matrigel impregnated with growth factors, as well as adenovirus expressing an inactive truncation mutant of the VEGF-R2 receptor. Gene delivery to the vascular compartment suppresses VEGF-R2 phosphorylation in these tissues ( Supplementary Fig. 2a, b) . Importantly, the VEGF-R2 truncation mutant restores the angiogenic response after PDGF/VEGF stimulation without affecting PDGF-mediated angiogenesis ( Fig. 1c ). These studies demonstrate that, in the presence of both VEGF and PDGF, VEGF-R2 can limit pro-angiogenic events.
We next considered the effect of VEGF treatment on PDGFstimulated pericyte recruitment to nascent vessels during angiogenesis. As expected, PDGF treatment alone produces a robust influx of alpha-smooth-muscle actin-expressing (a-SMA1; VSMC/pericyte marker) cells to the surface of patent blood vessels ( Fig. 2a ) 5 . However, stimulation of tissues with PDGF/VEGF results in a reduction in vascular pericyte coverage in comparison with tissues treated with PDGF alone. Importantly, pericyte coverage and neovascularization are restored after VEGF-R2 inhibition ( Fig. 2a ), suggesting that VSMC/pericyte VEGF-R2 negatively regulates this response.
To assess whether VSMC function could be influenced by the combination of PDGF and VEGF, we examined the effects of these growth factors on proliferation and migration in primary human VSMCs in vitro. Although PDGF induces VSMC proliferation and migration, exposure to both PDGF and VEGF results in a complete suppression of these responses (Fig. 2b) . In contrast, human umbilical vein endothelial cells (HUVECs), which express VEGF-R2 but not PDGF receptors, and normal human dermal fibroblasts (NHDFs), which express PDGF but not VEGF receptors ( Supplementary Fig. 3a ), exhibit robust migration and proliferation in the presence of PDGF/ VEGF. Similar results were obtained with a wide range of other endothelial cells and VSMC/pericytes ( Supplementary Fig. 4 ). Importantly, VSMCs pre-treated with a VEGF-R2 inhibitor or subjected to short interfering RNA (siRNA)-mediated knockdown of VEGF-R2, but not VEGF-R1, demonstrate complete reversal of PDGF/VEGFmediated suppression of cell migration and proliferation (Fig. 2c ). This may be explained by the finding that VEGF significantly attenuates PDGF-induced pp60-Src and ERK signalling ( Supplementary Fig. 5 ). Importantly, co-stimulation with bFGF and PDGF does not suppress PDGF-mediated VSMC chemotaxis (data not shown), further supporting a specific relationship between VEGF and PDGF.
The antagonistic results of PDGF/VEGF treatment do not result from competition for receptor occupancy because treatment with a range of VEGF doses fails to suppress PDGF stimulation of PDGF-Rb in NHDFs, which lack VEGF-R2 (data not shown). Thus, it appears that VEGF-ligation of VEGF-R2 in VSMCs leads to inactivation of PDGF-Rb, the dominant PDGF receptor on these cells. To test this possibility, VSMCs were exposed to varying concentrations of VEGF (in the presence or absence of PDGF) and the PDGF-Rb phosphorylation (activation) status was evaluated. Although VEGF alone fails to induce PDGF-Rb phosphorylation, it suppresses PDGF-mediated PDGF-Rb tyrosine phosphorylation fivefold, which can be reversed by PDGF titration ( Supplementary Fig. 6a, b ). Importantly, VEGF-121, which lacks a heparin-binding domain, also suppresses PDGFmediated activation of PDGF-Rb ( Supplementary Fig. 6c ). To evaluate the requirement of VEGF receptors for this process, we subjected VSMCs to VEGF-R1 or VEGF-R2 siRNA-mediated knockdown and analysed the effect of PDGF/VEGF co-stimulation on PDGF-Rb activity. Knockdown of VEGF-R2 but not VEGF-R1 abrogates the VEGF-mediated inactivation of PDGF-Rb, indicating that VEGF-R2 is essential for VEGF-mediated suppression of PDGF signalling in VSMCs (Fig. 3a) . VEGF-R2 kinase inhibition also restores PDGF-Rb phosphorylation in cells exposed to PDGF/VEGF, providing further evidence that VEGF-R2 negatively regulates PDGF-Rb ( Supplementary Fig. 7a ). Thus, co-stimulation of VSMCs with PDGF/VEGF results in cross-talk between the cognate receptors for these ligands, leading to suppression of PDGF signalling. To define the underlying mechanism of VEGF-R2-dependent inhibition of PDGF-Rb activity further, VEGF-R2 or VEGF-R2(D450C) were expressed in NHDF cells, which lack VEGF-R2. VEGF induces phosphorylation of wild-type VEGF-R2 but not the truncated derivative ( Supplementary Fig. 8a, b ). NHDF cells transduced with VEGF-R2 or VEGF-R2(D450C) demonstrate equivalent phosphorylation of PDGF-Rb in response to PDGF alone ( Fig. 3b ). However, when NHDFs expressing VEGF-R2 were stimulated with VEGF/PDGF, PDGF-Rb exhibited decreased phosphorylation relative to cells expressing truncated VEGF-R2. This was associated with a concomitant reduction in proliferation and cell migration, relative to cells exposed to either cytokine alone, demonstrating that VEGF-R2 expression is sufficient to inhibit PDGF-dependent function in VSMCs (Fig. 3b) .
Given the functional crosstalk between VEGF-R2 and PDGF-Rb in VSMCs, we evaluated whether these receptors interact directly by performing reciprocal co-immunoprecipitation studies. Importantly, treatment of VSMCs with PDGF/VEGF results in the formation of a previously undescribed VEGF-R2/PDGF-Rb complex, whereas no interaction is detected after exposure of cells to either growth factor alone (Fig. 3c ). The same biochemical interaction was not detected with PDGF-Ra ( Supplementary Fig. 9a ). Furthermore, pre-treatment of VSMCs with a VEGF-R2 inhibitor attenuates VEGF-R2/PDGF-Rb complex formation, suggesting a requirement for VEGF-R2 activity. Similar findings are observed in the pericyte-like 10T1/2 cell line, which is often used to approximate pericytes in vitro, and which has been found to exhibit growth suppression in co-culture with endothelial cells ( Supplementary Fig. 9b) 14, 15 . As a final biochemical confirmation, growth-factor-dependent PDGF-Rb/VEGF-R2 complex formation was identified in HEK-293 cells ectopically expressing both VEGF-R2 and PDGF-Rb ( Supplementary Fig. 9c ). To confirm these findings by using a cell biological approach, we performed a proximity ligation assay (PLA), which depicted close proximity of cellular molecules and demonstrated a fivefold increase in the VEGF-R2/PDGF-Rb interaction after PDGF/VEGF co-stimulation, relative to cells stimulated with either growth factor alone ( Supplementary Fig. 10 ). To characterize this interaction further, NHDFs were transduced with full-length or VEGF-R2(D450C). As demonstrated in VSMCs, expression of full-length VEGF-R2 but not the truncation mutant results in the formation of a VEGR-R2/PDGF-Rb complex (after dual cytokine stimulation only) (Fig. 3d) . These results demonstrate a requirement c, d, e, Representative reciprocal co-immunoprecipitation followed by immunoblot analysis with lysates derived from serum-starved VSMCs pretreated with either control or VEGF-R2 inhibitor (c), serum-starved NHDFs transduced with truncated VEGF-R2 adenovirus (d) or NHDFs transduced with VEGF-R2 catalytic site (Y1052F and Y1057F) and effector site mutants (Y1174F and Y1212F) (e). IB, immunoblot; IP, immunoprecipitation; WCL, whole-cell lysate; C-t, C terminus. Immunoblots are representative of at least three similar experiments; mutant receptors are characterized in Supplementary Fig. 8 .
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LETTERS for the VEGF-R2 carboxy (C) terminus in the VEGR-R2/PDGF-Rb interaction. We next transduced NHDFs with VEGF-R2(Y1052/1057F), which fails to undergo auto-phosphorylation in response to VEGF ( Supplementary Fig. 8e ). Similar to the results observed after transduction of VEGF-R2(D450C), this catalytically inactive mutant fails to complex with PDGF-Rb after treatment with dual growth factor, demonstrating that VEGF-R2 activity is required for interaction with PDGF-Rb (Fig. 3e) . Importantly, complex formation is still observed when two VEGF-R2 effector sites (Y1174 and Y1212) are mutated.
Tumours express high levels of VEGF and as a result develop tortuous, leaky and immature blood vessels 16, 17 . Anti-VEGF therapy results in vessel normalization characterized by increased pericyte coverage, tumour perfusion and chemotherapeutic sensitivity 18 . To investigate the role of VEGF in tumour vessel normalization, we examined the vasculature of fibrosarcomas that either express or lack VEGF 19 . Similar to results from anti-VEGF therapy, VEGF 2/2 tumours produce mature vessels with extensive pericyte coverage, whereas wild-type (VEGF 1/1 ) tumours develop an immature tumour vasculature with minimal pericyte coverage (Fig. 4a, b) . Importantly, dual expression of PDGF-Rb and VEGF-R2 appears limited to a-SMA1 perivascular cells ( Supplementary Fig. 11b ). Interestingly, the VEGF-R2/PDGF-Rb complex is only detected in lysates of VEGF 1/1 tumours, which feature an immature vasculature ( Fig. 4c ). By contrast, complex formation is attenuated in VEGF 2/2 tumours, concomitant with increased PDGF-Rb phosphorylation ( Fig. 4c ) and decreased VEGF-R2 phosphorylation ( Supplementary  Fig. 11a ). Next, we implanted human pancreatic tumour cells orthotopically into the tail of the mouse pancreas and allowed tumours to develop for two weeks. Analysis of immunoprecipitated protein from these tumours demonstrated PDGF-Rb/VEGF-R2 complex formation ( Supplementary Fig. 12a ). Although the tumour cells within these tissues express negligible levels of VEGF or PDGF receptors, we did observe co-expression of VEGF-R2 and PDGF-Rb on perivascular cells that co-stain with a-SMA ( Supplementary Fig.  12b, c) . Taken together, these studies demonstrate that VEGF can induce the formation of a VEGF-R2/PDGF-Rb complex implicated both in the suppression of pericyte function and in the regulation of tumour angiogenesis. Our findings support a mechanism where VEGF inhibits pericyte function and blood vessel maturation through the induction of a VEGF-R2/PDGF-Rb complex, and may in part, explain the molecular basis of anti-VEGF therapy in cancer patients.
METHODS SUMMARY
HUVECs, HMVECs, HAECs and NHDFs were acquired from Clonetics. Human aortic VSMCs were isolated from three donors (Clonetics and Cascade Biologicals). The pericyte line C3 10T1/2 (clone 8) was acquired from the American Type Culture Collection (ATCC). Murine lung endothelial cells (MLECs) were isolated by immunoselection using Dynal magnetic beads (Invitrogen). For in vitro studies, unless otherwise indicated, PDGF-BB, VEGF-165 and FGF-2 were used at 20 ng ml 21 , 40 ng ml 21 and 50 ng ml 21 , respectively. Growth factor (500 and 100 ng, respectively) was used for Matrigel and CAM experiments. Epitope-tagged mutant receptor constructs and adenoviruses were generated using standard cloning techniques and validated by DNA sequencing. The procedures for CAM 20 , Matrigel 21 and murine fibrosarcoma 19 experiments were performed with institutional approval as previously reported or with slight modifications. Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
METHODS
Cell culture and reagents. PDGF-BB (referred to as PDGF in the text) and VEGF-165 (referred to as VEGF in the text) were acquired from Peprotech; FGF-2 was from Chemicon. Endothelial cells were grown in EBM-2 media, NHDFs were grown in FGM media (Clonetics) and VSMCs were grown in Medium-231 (Cascade Biologicals). HEK-293T (ATCC) and C3 10T1/2 cells were grown in DMEM with 15% FBS-supplemented penicillin/streptomycin. Inhibitors SU-5416 (ref. 22 ) (VEGF-R2) and AG-1296 (PDGF-R) used at 1 mM were purchased from Calbiochem. Anti-VEGF-R2 (MAB-4431, R&D) was used at 50 mg ml 21 in Matrigel experiments. Antibodies to PDGF-Ra (sc-338), PDGF-Rb (sc-432), VEGF-R2 (sc-504), VEGF-R1 (sc-9029), ERK-2 (sc-1647), FAK (sc-557) and HRP-conjugated PY-20 (sc-508) were purchased from Santa Cruz Biotechnology. Other antibodies included p-ERK (Cell Signalling), p-FAK (Y861, Biosource), p-VEGF-R2 (Y1212, Upstate), p-VEGF-R2 (Y1052, Upstate) and p-VEGF-R2 (Y1175, Cell Signalling). Co-immunoprecipitation/immunoblotting. Two million cells in 150-cm dishes were starved in Basal SMC Media (Medium 231) with 0.2% FBS for 18 h. addition of growth factor was followed by a chilled PBS wash, and cell lysis proceeded after seven minutes in RIPA buffer (5 mM Tris pH 7.4, 150 mM NaCl, 1% Triton, 0.1 mM NaF) containing protease inhibitors (Minitab, Roche), 1 mM NaOV, and 10 mM PMSF. Clarified lysates were pre-incubated for 1 h with antibody followed by the addition of protein A/G beads (Pierce) for end-over-end tumbling at 4 uC overnight. Equal amounts of protein were subsequently resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting followed by detection with SuperSignal ECL (Pierce). Immunoprecipitation and immunoblotting of PDGF-Rb was with anti-PDGF-Rb (sc-432) and anti-PDGF-Rb (sc-339), respectively. Immunoprecipitation and immunoblotting of human VEGF-R2 was with anti-VEGF-R2 (sc-19530) and anti-VEGF-R2 (sc-504), respectively. Immunoprecipitation and immunoblotting of murine VEGF-R2 was with anti-VEGF-R2 (sc-504) and VEGF-R2 (sc-6251), respectively. Chemotaxis (Transwell) assay. Transwell assays were performed as previously described 23 . Proliferation (XTT) assay. Five thousand cells per well were seeded in 96-well plates. Cells were starved in Basal SMC Media (Medium 231) with 0.2% FBS for 18 h before the addition of growth factors. Incubation was for 48 h before addition of tetrazolium (XTT) salt from a Tox2 Kit (Sigma). VEGF receptor siRNA knockdown experiments. One million VSMCs were electroporated (Amaxa) with 80 pmol of scramble or VEGF-R1 or VEGF-R2 siRNA duplexes (Santa Cruz Biotechnology) 48 h before starvation for growth factor treatment experiments according to the protocol for AoSMC Nucleofection (Amaxa). Cells were recovered in 100-mm dishes in complete media. The following pooled siRNA sequences (Santa Cruz Biotechnology) were used to knockdown VEGF-R2 and VEGF-R1 respectively: VEGF-R2 siRNA sequences (mRNA accession number, NM_002253): duplex 1 sense strand, ACUGUGGUGAUUCCAUGUCTT; duplex 2 sense strand, ACUUGUAAACCGAGACCUATT; duplex 3 sense strand, CACCUGUUUGC-AAGAACUUTT; duplex 4 sense strand, AGACUACGUUGGAGCAAUCTT. VEGF-R1 siRNA sequences (mRNA accession number, NM_002019): duplex 1 sense strand, CACAUCGACAAACCAAUACTT; duplex 2 sense strand, ACACGAGAGUUCAAAUGACTT; duplex 3 sense strand, CAGAGACGU-UACUUGGAUUTT; duplex 4 sense strand, CAACAGGAUGGUAAAGACUTT. VEGF receptor adenovirus gene transfer. High-titre adenovirus was generated with the Adeasy system 24 (Stratagene) and applied to cells at a multiplicity of infection (MOI) of 50 plaque-forming units 48 h before experiments. Twenty microlitres of 10 11 plaque-forming units per millilitre titre viral stock was applied with growth factor for Matrigel assays.
Receptor transient transfection experiments. Two million HEK-293 cells seeded into 150-cm dishes were co-transfected with 10 mg pcDNA3 (Invitrogen) containing VEGF-R2 (cloned as a NotI/XhoI fragment from pBluescript SK-described below) or PDGF-Rb (a gift from C. Heldin) cDNAs using Lipofectamine 2000 (Invitrogen). Cells were starved 48 h later for growthfactor treatments. VEGF-R2 cloning and mutagenesis. Full-length murine VEGF-R2 cDNA was generated by PCR from a template reverse-transcribed from murine lung RNA (see RT-PCR) using Platinum Taq High Fidelity (Invitrogen) with a DNA Engine (PTC-200, Bio-Rad cycler as follows: 94 uC for 30 s, followed by 94 uC for 15 s, 55 uC for 30 s, and 68 uC for 5 min for 30 cycles). NotI and XhoI restriction sites (underlined) were introduced by PCR to generate full-length murine VEGF-R2 (4085 base pairs (bp)) and C-terminal-truncated VEGF-R2(D450C), 2750 bp as follows: 59 NotI primer corresponds to nucleotides 211-232 of VEGF-R2: GCGGCCGCGCGGCCGCAAGGAGTCTGTGCCTGA-GAACT. The 39 XhoI primer for full-length VEGF-R2 was CTCGA-GCTCGAGAACAGGAGGTGAGCGCAG; the 39 XhoI primer for truncated VEGF-R2 was CTCGAGCTCGAGTAGGAGGTTCACCACATTGAGA. Ligation of purified PCR products was into a NotI/XhoI site of pShuttle-IRES-hrGFP2 (Stratagene) in-frame with a triple-HA epitope tag. All constructs were subjected to DNA sequencing. Each shuttle vector was linearized with PmeI and electroporated into Escherichia coli BJ5183 cells for homologous recombination and selection. High-titre adenovirus was generated in HEK293T cells (ATCC) through the transfection of 5 mg, linearized recombinant pAd-1 plasmid with Lipofectamine 2000 (Invitrogen) according to published methods 24 .
Site-directed mutagenesis (for tyrosine-to-phenylalanine mutations) required sub-cloning of a 4.1-kilobase NotI/XhoI fragment containing the VEGF-R2 open reading frame into pBluescript SK-(Stratagene). All results were verified by DNA sequencing, western blotting and flow-cytometry. The following primer pairs (mutant nucleotide exchange is underlined) were used in the mutagenesis reactions using a QuickChange kit (Stratagene) and an annealing temperature of 68 uC: Y1052F sense (GCTTGGCCCGGGACATTTTTAAAGACCCGGATT) and antisense (CGAACCGGGCCCTGTAAAAATTTCTGGGCCTAA); Y1057F sense (CCGGGACATTTATAAAGACCCGGATTTTGTCAGAAAAGGAG) and antisense (GGCCCTGTAAATATTTCTGGGCCTAAAACAGTCTTTTCCTC); Y1173F sense (CAGCAGGATGGCAAAGACTTTATTGTTCTTCCAATGTCA) and antisense (TGACATTGGAAGAACAATAAAGTCTTTGCCATCCTGCTG); Y1212F sense (AGTGTGCGACCCCAAATTCCATTTTGACAACACAGC) and antisense (GCTGTGTTGTCAAAATGGAATTTGGGGTCGCACACT). VEGF receptor expression (semi-quantitative RT-PCR). Total cellular RNA from HUVECs, VSMCs and NHDFs was extracted using Trizol Reagent (Invitrogen). Reverse transcription was performed with a Superscript II Two-
Step RT-PCR Kit (Invitrogen). The resultant cDNA template used for PCR reactions included the following primers for human gene products: VEGF-R1 59-GCGACGTGTGGTCTTACG, 59-GGCGACTGCAAAAGTCCT; VEGF-R2 59-CATCCAGTGGGCTGATGA, 59-TGCCACTTCCAAAAGCAA; VEGF-R3 59-GATGCGGGACCGTATCTG, 59-ATCCTCGGAGCCTTCCAC; GAPDH 59-AAGGGCATCCTGGGCTAC, 59-GTGGAGGAGTGGGTGTCG. For murine gene products, the following primers were used for PCR reactions: VEGF-R1 59-GGAGGAAGAGGATGCGGCA, 59-GAAGCTGTGCTATGTTGCTCTA; VEGF-R2 59-TTCCAGATGCTGGGCAAGTC, 59-ATGACATCTTGATTGTGGCAT; VEGF-R3 59-TGCATGCTGGGTGGACTATCA, 59-GCAGGAGGAGGAAGAG-GAGC; b-actin 59-GGAGGAAGAGGATGCGGCA, 59-GAAGCTGTGCTAT-GTTGCTCTA. Proximity ligation assay. PLA was performed to image protein-protein interactions using microscopy. In brief, oligonucleotide conjugated 'probe' antibodies are directed against primary antibodies raised against cell-surface receptors. Annealing of the 'probes' occurs when the target proteins are in close proximity, which initiates the amplification of a Texas red reporter signal. VSMCs grown on coverslips were starved for 18 h and treated with 20 ng ml 21 PDGF, 40 ng ml 21 VEGF or both for 7 min. Cells were washed with chilled PBS and fixed with 4% paraformaldehyde for 15 min, blocked and permeabilized with 5% goat serum (MP Biomedicals) containing 0.2% Triton, and incubated overnight with anti-VEGF-R2 (sc-504) and anti-PDGF-Rb (sc-432). Proximity ligation was performed according to the manufacturer's protocol 25, 26 using the Duolink Detection Kit with PLA PLUS and MINUS Probes for mouse and rabbit (Olink Bioscience). Hoechst stain was included in the Duolink Detection Kit while anti-Phalloidin Alexa488 at 1:5,000 (Invitrogen) was added during the detection reaction. Specimens were mounted with Vectashield mounting media (Vector Laboratories) and examined with an epi-fluorescence microscope (Olympus IX-51) under a 360 oil objective. Texas-red signal amplification was skeletonized in only the red channel in Metamorph Imaging Software 7.1 (Molecular Devices) for assessment of pixel counts after applying a constant threshold value of 240 (termed 'signal' in the text). Four 360 oil fields were randomly chosen for analysis and averaged per condition examining four separate samples separately. Flow cytometry. Fluorescence-activated cell sorting with a FACSCaliber (BD) was performed using standard techniques on live cells using anti-PDGF-Ra (sc-338), anti-PDGF-Rb (sc-432) and anti-VEGF-R2 (BD) for murine VEGF-R2. Alexa647-conjugated antibodies were used for detection (Invitrogen). MLEC isolation. MLECs were isolated from 15-week-old C57Bl/6 mice. Briefly, the lungs were excised from euthanized mice, minced and digested with 1 mg ml 21 collagenase A/dispase (Roche) in RPMI media. Digested tissue was filtered through a 100-mm nylon cell strainer (BD), and the cell suspension was plated onto collagen-coated dishes. After 3 days, endothelial cells were isolated by immunoselection using Dynal magnetic beads (Invitrogen) conjugated with 5 mg anti-mouse CD-31 and CD-102. Cells were propagated in EBM-2 media supplemented with EBM-2 microvascular SingleQuots (Lonza). CAM angiogenesis assay. Chick CAM experiments have been previously described 20 . Inhibitors were applied to CAMs 24 h before treatment with growth factor.
